Accretion Pharmaceuticals Ltd.

Accretion Pharmaceuticals Ltd.

NNSE:ACCPL
205.25
INR
-10.75
(-4.98%)
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

CEO
Vivek Ashok Kumar Patel
Full Time Employees
132
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Ahmedabad India
IPO Date
May 21, 2025
Business
Accretion Pharmaceuticals Ltd. is an India-based pharmaceutical company engaged in the research, development, manufacturing, and commercialization of generic formulations, active pharmaceutical ingredients (APIs), and specialized healthcare products. The company operates across three core business segments: Finished Dosage Formulations, Active Pharmaceutical Ingredients (APIs), and Contract Development and Manufacturing (CDMO) Services. Its product and service portfolio includes oral solid dosage forms, such as immediate-release, sustained-release, and dispersible tablets; hard and soft gelatin capsules; oral liquid formulations, including syrups, suspensions, and pediatric drops; sterile parenteral preparations, including small-volume liquid injectables and lyophilized powders; topical dermatological formulations, encompassing therapeutic creams, gels, and ointments; bulk active pharmaceutical ingredients and specialty advanced chemical intermediates; nutraceutical formulations, multivitamins, and dietary wellness supplements spanning key therapeutic segments including anti-infectives, cardiovascular disease, gastroenterology, pain management, respiratory conditions, and metabolic disorders; and custom CDMO solutions, featuring formulation development, analytical method validation, scale-up batch production, stability testing, and regulatory dossier compilation for third-party institutional clients. Accretion Pharmaceuticals Ltd. serves domestic and international markets, distributing products to public healthcare agencies, private hospital networks, pharmacy chains, and pharmaceutical marketers across India, while exporting to emerging markets in Southeast Asia, Africa, the Middle East, and Latin America. Founded in 2012 and headquartered in Ahmedabad, India, the company operates modern manufacturing infrastructure compliant with WHO-GMP standards. In recent developments, Accretion Pharmaceuticals Ltd. completed its listing on the National Stock Exchange of India (NSE: ACCPL) to support manufacturing expansion and operational scaling. The company has expanded its manufacturing capacity through the commissioning of a specialized sterile injectable line, entered into strategic co-marketing and distribution agreements in emerging export territories, launched an advanced portfolio of chronic care formulations targeting cardiovascular and diabetes management, and reorganized its contract research and development division to accelerate high-barrier generic product launches.